Work

Phase Ia study of VRN101099, a brain-penetrant, highly selective covalent HER2 inhibitor, in HER2-positive or HER2-mutant advanced solid tumors.

Year: 2026

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2026.44.16_suppl.1048

Authors: Jee Hung Kim, Rasha Cosman, Christopher Steer, Jieun Lee, Jee Hyun Kim, Sun Young Rha, Seock-Ah Im, Yeon Hee Park, Kyung Hae Jung, Shuang Yin Zhang

Institutions: Seoul National University, Yonsei University, Seoul National University Bundang Hospital, Gangnam Severance Hospital, Garvan Institute of Medical Research, UNSW Sydney, St Vincent's Hospital Sydney, The Kinghorn Cancer Centre, The Catholic University of Korea Seoul St. Mary's Hospital, Catholic University of Korea, Yonsei University Health System, Yonsei Cancer Hospital, Seoul National University Hospital, Samsung Medical Center, Sungkyunkwan University, Asan Medical Center, University of Ulsan

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7162549988

Cites:

Cited by:

Related to: